# Trabectedin First Line Therapy In Unfit Sarcoma Study

> **NCT02066675** · PHASE2 · COMPLETED · sponsor: **Italian Sarcoma Group** · enrollment: 24 (actual)

## Conditions studied

- Metastatic and Locally Advanced Soft Tissue Tumor Patients Unfit to Receive
- Standard Chemotherapy

## Interventions

- **DRUG:** Trabectedin

## Key facts

- **NCT ID:** NCT02066675
- **Lead sponsor:** Italian Sarcoma Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2016-12-31
- **Final completion:** 2016-12-31
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2018-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02066675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02066675, "Trabectedin First Line Therapy In Unfit Sarcoma Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02066675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*